145 related articles for article (PubMed ID: 37065601)
1. Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies.
Le UT; Passlick B; Schmid S
J Thorac Dis; 2023 Mar; 15(3):1133-1141. PubMed ID: 37065601
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
[TBL] [Abstract][Full Text] [Related]
3. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
De B; Venkatesan AM; Msaouel P; Ghia AJ; Li J; Yeboa DN; Nguyen QN; Bishop AJ; Jonasch E; Shah AY; Campbell MT; Wang J; Zurita-Saavedra AJ; Karam JA; Wood CG; Matin SF; Tannir NM; Tang C
BJU Int; 2022 May; 129(5):610-620. PubMed ID: 34228889
[TBL] [Abstract][Full Text] [Related]
4. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.
Joosten PJM; de Langen AJ; van der Noort V; Monkhorst K; Klomp HM; Veenhof AAFA; Dickhoff C; Smit EF; Hartemink KJ
Lung Cancer; 2021 Nov; 161():141-151. PubMed ID: 34600405
[TBL] [Abstract][Full Text] [Related]
5. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma.
Schoenhals JE; Mohamad O; Christie A; Zhang Y; Li D; Singla N; Bowman I; Arafat W; Hammers H; Courtney K; Cole S; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Adv Radiat Oncol; 2021; 6(5):100692. PubMed ID: 34646963
[TBL] [Abstract][Full Text] [Related]
7. Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade.
Sindhu KK; Leiter A; Moshier E; Lin JY; Carroll E; Brooks D; Shimol JB; Eisenberg E; Gallagher EJ; Stock RG; Galsky MD; Buckstein M
Cancer Treat Res Commun; 2020; 25():100216. PubMed ID: 33049542
[TBL] [Abstract][Full Text] [Related]
8. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
10. Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy.
Sindhu KK; Nehlsen AD; Lehrer EJ; Rowley JP; Stock RG; Galsky MD; Buckstein M
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289743
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; Tanadini-Lang S; Mayinger M; Guckenberger M; Andratschke N
Clin Transl Radiat Oncol; 2024 Mar; 45():100748. PubMed ID: 38433950
[TBL] [Abstract][Full Text] [Related]
13. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.
Ni Y; Liu B; Ye X; Fan W; Bi J; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
Cardiovasc Intervent Radiol; 2019 May; 42(5):693-699. PubMed ID: 30701290
[TBL] [Abstract][Full Text] [Related]
14. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade.
Mahmood U; Huynh MA; Killoran JH; Qian JM; Bent EH; Aizer AA; Mak RH; Mamon HJ; Balboni TA; Gunasti L; Ott PA; Awad MM; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):666-675. PubMed ID: 35643252
[TBL] [Abstract][Full Text] [Related]
16. Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma.
Barata PC; Mendiratta P; Kotecha R; Gopalakrishnan D; Juloori A; Chao ST; Koshkin V; Ornstein M; Gilligan TD; Wood LS; Rini BI; Angelov L; Garcia JA
Clin Genitourin Cancer; 2018 Oct; 16(5):413-419.e1. PubMed ID: 30172552
[TBL] [Abstract][Full Text] [Related]
17. The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma.
Guida M; Bartolomeo N; De Risi I; Fucci L; Armenio A; Filannino R; Ruggieri E; Macina F; Traversa M; Nardone A; Figliuolo F; De Luca F; Mele F; Tommasi S; Strippoli S
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31615127
[No Abstract] [Full Text] [Related]
18. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.
Wang Z; Wei L; Li J; Zhou H; Li S; Chen D; Yu Y; Zhao L; Zhu X; Song Y
Transl Lung Cancer Res; 2021 Dec; 10(12):4368-4379. PubMed ID: 35070747
[TBL] [Abstract][Full Text] [Related]
19. Bombarding Oligoprogression: Oncologic Outcomes After Radiation to Patients With Oligoprogressive Non-Small Cell Lung Cancer on Maintenance Systemic Therapy.
Chou B; Lee JH; Saetern L; Venkatesulu BP; Welsh JS; Harkenrider MM
Am J Clin Oncol; 2024 Apr; 47(4):155-160. PubMed ID: 38193499
[TBL] [Abstract][Full Text] [Related]
20. Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.
Seidel C; Fenner M; Merseburger AS; Reuter C; Ivanyi P; Länger F; Ganser A; Grünwald V
World J Urol; 2011 Jun; 29(3):355-60. PubMed ID: 21258806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
